uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:QURE
CUSIPN/A
Phone31-20-566-7394
Debt
Debt-to-Equity Ratio0.16
Current Ratio5.48
Quick Ratio5.48
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.11 million
Price / Sales96.39
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book11.76
Profitability
EPS (Most Recent Fiscal Year)($2.94)
Net Income$-79,260,000.00
Net Margins-586.38%
Return on Equity-131.55%
Return on Assets-44.52%
Miscellaneous
Employees202
Outstanding Shares37,070,000
Market Cap$1,263.68
Uniqure (NASDAQ:QURE) Frequently Asked Questions
What is Uniqure's stock symbol?
Uniqure trades on the NASDAQ under the ticker symbol "QURE."
How were Uniqure's earnings last quarter?
Uniqure NV (NASDAQ:QURE) issued its quarterly earnings data on Monday, April, 30th. The biotechnology company reported ($0.59) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.74) by $0.15. The biotechnology company had revenue of $3.48 million for the quarter, compared to analysts' expectations of $3.08 million. Uniqure had a negative return on equity of 131.55% and a negative net margin of 586.38%. View Uniqure's Earnings History.
When is Uniqure's next earnings date?
What price target have analysts set for QURE?
9 Wall Street analysts have issued twelve-month price targets for Uniqure's stock. Their predictions range from $13.00 to $63.00. On average, they anticipate Uniqure's stock price to reach $39.3750 in the next twelve months. This suggests a possible upside of 15.5% from the stock's current price. View Analyst Ratings for Uniqure.
What is the consensus analysts' recommendation for Uniqure?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Uniqure in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Uniqure's key competitors?
Some companies that are related to Uniqure include Ligand Pharmaceuticals (LGND), Dr.Reddy's Laboratories (RDY), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Evotec (EVTCY), The Medicines (MDCO), Horizon Pharma (HZNP) and Ascendis Pharma A/S (ASND).
Who are Uniqure's key executives?
Uniqure's management team includes the folowing people:
- Mr. Matthew Craig Kapusta, CEO, Interim CFO & Exec. Director (Age 46)
- Dr. Sander Van Deventer, Co-Founder, Chief Scientific Officer, Director, Advisor & GM of Amsterdam (Age 64)
- Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
- Dr. Scott T. McMillan Ph.D., Chief Operating Officer (Age 59)
- Mr. Christian Klemt, Chief Accounting Officer (Age 45)
Has Uniqure been receiving favorable news coverage?
Media stories about QURE stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Uniqure earned a daily sentiment score of 0.15 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 45.89 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Uniqure's major shareholders?
Uniqure's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FORUNIQURE B.V. (13.81%), COLLER INTERNATIONAL PARTNERS V A LP (5.73%), Fred Alger Management Inc. (0.07%), Atria Investments LLC (0.02%) and FORBION COMPANY -INVESTMENT II COOPERATIEF U.A. (5.00%). Company insiders that own Uniqure stock include Christian Klemt, David Schaffer, Deventer Sander Van, Harald Petry, Maria E Cantor, Matthew C Kapusta and Steven Zelenkofske. View Institutional Ownership Trends for Uniqure.
Which major investors are buying Uniqure stock?
How do I buy shares of Uniqure?
Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Uniqure's stock price today?
One share of QURE stock can currently be purchased for approximately $34.09.
How big of a company is Uniqure?
Uniqure has a market capitalization of $1.26 billion and generates $13.11 million in revenue each year. The biotechnology company earns $-79,260,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Uniqure employs 202 workers across the globe.
How can I contact Uniqure?
Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-566-7394 or via email at [email protected]
MarketBeat Community Rating for Uniqure (NASDAQ QURE)
MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote "Outperform" if you believe QURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.
